Neoadjuvant of Sintilimab Combined Weekly Metronomic Chemotherapy (POLF) for Resectable Locally Advanced Gastric Cancer

To evaluate efficacy and safety of Neoadjuvant of Sintilimab Combined Weekly Metronomic Chemotherapy (POLF) in resectable locally advanced gastric cancer.

Trial Details

NCT ID
NCT06054906
Phase
PHASE2
Sponsor
Huashan Hospital
Status
RECRUITING
Cancer Type
Gastric Cancer
Interventions
  • sintilimab+metronomic POLF
Locations (sample)
  • Shanghai, China|31.22222,121.45806

Key Eligibility Criteria

  • Signed written Informed Consent Form
  • Male or female, age ≥ 18 years old
  • Histologically confirmed gastric adenocarcinoma, diagnosed as locally progressive according to the AJCC 8th ed, cTNM diagnosis of cT3-4aN1-3M0 and …
  • No prior systemic therapy such as surgery, radiotherapy, or immunotherapy for the disease at hand

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Gastric Cancer Trials on Trialify →